Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CureVac NV
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.
After a baptism of fire during the coronavirus pandemic, mRNA vaccine technology has earned its stripes. In less than a year, mRNA vaccines have been catapulted from interesting pipeline prospects to game-changers in the fight against COVID-19. But what does this success mean for the future of the technology?
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- CureVac GmbH
- CureVac BV